The Nicolet business develops clinically differentiated neurodiagnostic and monitoring products including a portfolio of electroencephalography (EEG) and electromyography (EMG) systems, as well as vascular and obstetric doppler sensors and connectivity products.

The acquisition is likely to close in July 2012, subject to customary closing conditions.

CareFusion chairman and CEO Kieran Gallahue said the decision to divest the Nicolet business is in line with the company’s strategy to simplify and focus its operations and prioritise the investments to profitably grow over the long term.

Natus CEO Jim Hawkins said the Nicolet acquisition will strengthen the company’s existing neurology portfolio and provide them with new product categories.

CareFusion’s product line includes Alaris infusion pumps, Pyxis automated dispensing and patient identification systems, AVEA, AirLife and LTV series ventilation and respiratory products, ChloraPrep skin prep products, MedMined services for data mining surveillance, Nicolet neurological monitoring and diagnostic products and V. Mueller surgical instruments.